Dan Ou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Ou has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Chaosu Hu
Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
40 shared publications - Xiayun He
Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China
40 shared publications - Bin Wu
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
39 shared publications - Changming Zhou
Department of Respiratory Disease, The First Affiliated Hospital of Bengbu Medical College , Bengbu , China
39 shared publications - Dongmei Ji
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
39 shared publications - Hongmei Ying
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University Shanghai Cancer Center, Shanghai, China
39 shared publications
Latest Publications
- Open Access
- 1 February 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (4) , e6578
Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
Purpose: Intensity‐modulated radiotherapy (IMRT) combined with concurrent chemotherapy is deemed as the mainstay treatment in locoregionally advanced nasopharyngeal carcinoma (NPC). Nevertheless, the tolerance of severe acute toxicity of concurrent chemotherapy was unsatisfied. In addition, T4 is the predicting factor of poor prognosis for NPC patients. In this retrospective analysis, the long‐term outcomes IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy for T4 non‐metastatic NPC were analyzed.Materials and Methods: From January 2005 to November 2016, a total of 145 biopsy‐proven non‐metastatic T4 NPC was treated with IMRT combined by induction chemotherapy with or without adjuvant chemotherapy. The survival and side effects of the patients were analyzed.Results: Median follow‐up time was 74 months (ranges, 8–186 months). 10.0%, 61.3%, 27.3%, and 1.3% developed grade 1, 2, 3, and 4 mucositis during IMRT, respectively. 5.5% and 2.0% patients experienced grade 1 and 2 nausea and vomiting; no patients developed grade 3 or 4 nausea and vomiting. Of 145 patients enrolled, 5‐year and 10‐year overall survival(OS) rates were 73.7% and 53.9%, local progression‐free survival(LPFS) rates were 86.1% and 71.6%, regional progression‐free survival(RPFS) rates were 96.7% and 92.8%, distant metastasis‐free survival (DMFS) rates were 86.7%, 78.2%, respectively. At the last follow‐up, five patients developed cranial nerve injury, one patient developed mandibular bone necrosis, four patients developed temporal lobe injury, four patients developed nasopharyngeal massive hemorrhage (three cases after recurrence and one case without recurrence), and five patients developed second primary tumor.Conclusion: The survival outcomes of treating T4 NPC IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy are encouraging. Moreover, mucosal reaction, nausea, and vomiting reaction were reduced during IMRT.
- 1 February 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (4) , e6578
Open AccessDeletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
Purpose: Intensity‐modulated radiotherapy (IMRT) combined with concurrent chemotherapy is deemed as the mainstay treatment in locoregionally advanced nasopharyngeal carcinoma (NPC). Nevertheless, the tolerance of severe acute toxicity of concurrent chemotherapy was unsatisfied. In addition, T4 is the predicting factor of poor prognosis for NPC patients. In this retrospective analysis, the long‐term outcomes IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy for T4 non‐metastatic NPC were analyzed.Materials and Methods: From January 2005 to November 2016, a total of 145 biopsy‐proven non‐metastatic T4 NPC was treated with IMRT combined by induction chemotherapy with or without adjuvant chemotherapy. The survival and side effects of the patients were analyzed.Results: Median follow‐up time was 74 months (ranges, 8–186 months). 10.0%, 61.3%, 27.3%, and 1.3% developed grade 1, 2, 3, and 4 mucositis during IMRT, respectively. 5.5% and 2.0% patients experienced grade 1 and 2 nausea and vomiting; no patients developed grade 3 or 4 nausea and vomiting. Of 145 patients enrolled, 5‐year and 10‐year overall survival(OS) rates were 73.7% and 53.9%, local progression‐free survival(LPFS) rates were 86.1% and 71.6%, regional progression‐free survival(RPFS) rates were 96.7% and 92.8%, distant metastasis‐free survival (DMFS) rates were 86.7%, 78.2%, respectively. At the last follow‐up, five patients developed cranial nerve injury, one patient developed mandibular bone necrosis, four patients developed temporal lobe injury, four patients developed nasopharyngeal massive hemorrhage (three cases after recurrence and one case without recurrence), and five patients developed second primary tumor.Conclusion: The survival outcomes of treating T4 NPC IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy are encouraging. Moreover, mucosal reaction, nausea, and vomiting reaction were reduced during IMRT.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Overall response rate of induction chemoimmunotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Overall response rate of induction chemoimmunotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Changes of quality of life at different timepoints
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Changes of quality of life at different timepoints
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups